John Chorba, MD

Assistant Adjunct Professor

Cardiology, Cardiology ZSFG

My interests lie in using chemical tools to probe biological mechanisms of disease, with the ultimate goal of developing a better understanding of heart disease to develop novel therapeutics. Currently, my work focuses on the processing mechanisms of PCSK9, a protein that causes elevated cholesterol levels, so as to develop new drug targets against atherosclerosis.

Education
Cardiology Fellowship, 2014 - , University of California, San Francisco
Internal Medicine Residency, 2010 - , Massachusetts General Hospital
M.D., 2007 - , Harvard Medical School
Honors and Awards
  • K08 Mentored Clinical Scientist Development Award, NIH/NHLBI, 2015-2020
  • ASPIRE Cardiovascular Award, Pfizer, 2015-2018
  • Hellman Fellowship, Hellman Fellows Fund, 2015-2017
  • Pilot Investigator Award, UCSF Academic Senate, 2015-2017
  • Catalyst Award, UCSF CTSI, 2015-2016
  • Loan Repayment Program, NIH/NHLBI, 2013-2017
  • Research Scholar in Cardiovascular Disease Award, Gilead Sciences, 2013-2016
  • Ruth L. Kirschstein F32 National Research Service Award, NIH/NHLBI, 2012-2014
  • Laennec Young Clinician Award, American Heart Association, 2011
Publications
  1. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
  2. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing.
  3. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
  4. A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9.
  5. Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.
  6. Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.
  7. An Educational and Administrative Intervention to Promote Rational Laboratory Test Ordering on an Academic General Medicine Service.
  8. The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.
  9. Brain natriuretic peptide predicts functional outcome in ischemic stroke.
  10. Sustained ventricular fibrillation in a conscious patient.
  11. Vesicular stomatitis viruses resistant to the methylase inhibitor sinefungin upregulate RNA synthesis and reveal mutations that affect mRNA cap methylation.
  12. Novel inhibitors of IMPDH: a highly potent and selective quinolone-based series.
  13. Quinolone-based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues.